Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K7 | O43318 | 4/20 | 0.76 |
| ▸ | IRAK1 | P51617 | 4/20 | 0.76 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.76 |
| ▸ | EGFR | P00533 | 8/20 | 0.73 |
| ▸ | TEC | P42680 | 4/20 | 0.56 |
| ▸ | TXK | P42681 | 3/20 | 0.55 |
| ▸ | ITK | Q08881 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16755420 | 0.94 | EGFR (0.70) | MAP3K7IRAK1IRAK4EGFRTEC | |
| SCHEMBL16755398 | 0.89 | EGFR (0.79) | MAP3K7IRAK1IRAK4EGFRTEC | |
| SCHEMBL16767965 | 0.89 | EGFR (0.81) | MAP3K7IRAK1IRAK4EGFRTEC | |
| SCHEMBL1924466 | 0.87 | MAP3K7 (1.00) | MAP3K7IRAK1IRAK4EGFR | |
| SCHEMBL16755403 | 0.87 | EGFR (0.78) | MAP3K7IRAK1IRAK4EGFRTEC | |
| SCHEMBL1924565 | 0.86 | MAP3K7 (0.86) | MAP3K7IRAK1IRAK4EGFR | |
| SCHEMBL29313976 | 0.86 | MAP3K7 (0.85) | MAP3K7IRAK1IRAK4EGFR | |
| SCHEMBL1923717 | 0.86 | MAP3K7 (0.88) | MAP3K7IRAK1IRAK4EGFR | |
| SCHEMBL16755401 | 0.85 | EGFR (0.75) | MAP3K7IRAK1IRAK4EGFRTEC | |
| SCHEMBL16755455 | 0.85 | EGFR (0.75) | MAP3K7IRAK1IRAK4EGFRTEC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152083-A1 | Compounds and Compositions for Modulating EGFR Activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-06-04 | — | — | US | claimed |
| US-20150152083-A1 | Compounds and Compositions for Modulating EGFR Activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-06-04 | — | — | US | disclosed |
| US-20150152083-A1 | Compounds and Compositions for Modulating EGFR Activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-06-04 | — | — | US | disclosed |
| US-20150152083-A1 | Compounds and Compositions for Modulating EGFR Activity | IRM LLC, A DELAWARE LIMITED LIABILITY COMPANY (BM) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152083-A1 | Compounds and Compositions for Modulating EGFR Activity | EGFR, ERBB2, ERBB3 | MAP3K7 183/4885IRAK1 1352/4885IRAK4 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.